CLINICAL STUDIES
Mirabilis completes first human trial with HIFU system uterine fibroid treatment
 Volunteer patients were treated with the Mirabilis system just prior to scheduled hysterectomies, after which the excised uterine tissue was examined by a pathologist for effects of treatment, according to the Bothell, Wash.-based company. The company said that the analysis demonstrated successful creation of lesions within the target zone. “We continue to develop several advanced features in preparation for future efficacy studies in patients with fibroids,” said Mirabilis CEO Mike Connolly. An estimated 16 million in the United States suffer fibroid symptoms at some point in their life, leading to 250,000 annual U.S. hysterectomies. |
